Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Vall D Hebron Institute Of Oncology
Sponsor

Vall D Hebron Institute Of Oncology

Spain Calle Natzaret 115, 08035 Barcelona, Spain

About the sponsor

Research activity includes metastatic colorectal cancer, BRAF V600E-mutant mCRC, microsatellite stable and microsatellite instable colorectal disease, as well as gastric cancer and gastroesophageal junction cancer.

  • BRAF-targeted treatment strategies
  • Rechallenge approaches in metastatic disease
  • Neoadjuvant treatment for gastric and GEJ cancer
  • Colorectal and endometrial tumors with mismatch repair features

The portfolio also covers antibody-based and immune-based combinations in advanced digestive tract malignancies.

About Specializations

Vall D Hebron Institute Of Oncology runs clinical trials in conditions such as Colorectal cancer metastatic, Gastric cancer, BRAF V600E mutation positive, Neoplasm, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

12 clinical trials

Colorectal cancer metastatic+1

Recruiting

Study of encorafenib and cetuximab treatment for patients with BRAF V600E-mutant metastatic colorectal cancer who previously responded to BRAF inhibitor therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Encorafenib
  • Sponsor:Vall D Hebron Institute Of Oncology

Neoplasm+2

Recruiting

Study Comparing ANV419 and High Dose IL2 in Adoptive Cell Therapy for Patients with Melanoma, Non-Small Cell Lung Cancer, and Cervical Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Vall D Hebron Institute Of Oncology

Neoplasm malignant

Recruiting

Study on Atezolizumab, Amivantamab, and Futibatinib for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Vall D Hebron Institute Of Oncology

Gastric cancer+1

Recruiting

Study of Avelumab with Chemotherapy for Patients with Resectable Stomach or Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Endometrial cancer+3

Recruiting

Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Colorectal cancer metastatic

Recruiting

Study on Bevacizumab, Encorafenib, and Cetuximab for Patients with BRAF-V600E Mutated Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Adrenocortical carcinoma

Recruiting

Study on Mitotane Alone or with Cisplatin and Etoposide for Patients with High-Risk Adrenocortical Carcinoma After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Amsterdam UMC Stichting

Gastric cancer

Not yet recruiting

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Clear cell renal cell carcinoma

Not yet recruiting

A study of pembrolizumab, belzutifan, and lenvatinib before main treatment in patients with localized kidney cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Vall D Hebron Institute Of Oncology

Osteosarcoma metastatic

Not yet recruiting

Study on the Safety and Tumor-Fighting Effects of OMO-103 for Patients with Advanced Osteosarcoma

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:OMO-103
  • Sponsor:Vall D Hebron Institute Of Oncology

Endometrial cancer recurrent

Not recruiting

Study on the Safety and Effectiveness of Lurbinectedin and Dostarlimab for Patients with Advanced Endometrial Cancer After Platinum-based Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Vall D Hebron Institute Of Oncology

Colorectal cancer metastatic+1

Not recruiting

Study of Durvalumab and Tremelimumab for Patients with Colorectal and Endometrial Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.